FDA approves Inlexzo for bladder cancer
The U.S. Food and Drug Administration has approved Inlexzo (gemcitabine intravesical system) for the treatment of patients with certain types of bladder cancer.
Sep 11, 2025
0
19
Urology news
Can grape seed extract slow the growth of prostate cancer after treatment?
Grape seed extract—a dietary supplement made from the seeds of wine grapes—has been investigated to see if it can help reduce blood cholesterol levels and high blood pressure. But can it also help slow down the growth of ...
Oct 23, 2025
0
19
New therapeutic strategies show promise against a hard-to-treat prostate cancer
A new study has uncovered promising therapeutic strategies against one of the deadliest forms of prostate cancer.
Nov 20, 2025
0
19
Treatment developed for advanced prostate cancer that could eliminate severe side effects
Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a side effect so debilitating that patients often refuse the life-saving therapy.
Jan 7, 2026
0
19
Study suggests type 1 diabetes may significantly raise bladder cancer risk
People with type 1 diabetes (previously called juvenile diabetes) are 4.29 times more likely to develop bladder cancer, according to a systematic review and meta-analysis by researchers at the Keck School of Medicine of USC. ...
Nov 20, 2025
0
19
Dual targeted therapy shows promise in previously treated advanced kidney cancer patients
Results from a trial led by researchers from The University of Texas MD Anderson Cancer Center showed that a targeted therapy combination improved outcomes for patients with metastatic clear-cell renal carcinoma (ccRCC)—a ...
Oct 20, 2025
0
19
Sustained reduction found in prostate cancer mortality with prostate-specific antigen screening
A European study has demonstrated a sustained long-term reduction in prostate cancer mortality through prostate-specific antigen (PSA) screening. However, the findings also highlight the issue of overdiagnosis, or the detection ...
Nov 4, 2025
0
19
Cellular signature explains why some prostate tumors resist standard treatments
A new study by University of Michigan Rogel Cancer Center researchers identifies a cellular signature that explains why about one-third of prostate cancers respond especially poorly to treatment.
Jul 9, 2025
0
19
Researchers turn cancer resistance mutations into targets for new immunotherapies
One of the most challenging moments in cancer treatment comes when a therapy stops working. In many metastatic cancers, drugs that are initially effective lose their potency over time, as malignant cells acquire mutations ...
Dec 29, 2025
0
19
Chemical variations in prostate cancer calcifications analyzed to identify new diagnostic markers
Researchers at Keele University have published the first investigation into the variation in the chemical makeup of calcifications caused by prostate cancer, in the hope of identifying new markers to improve early diagnosis.
Jul 22, 2025
0
19
